



3rd Edition

Programme

MedFIT

Fostering Innovation in medTech

JUNE
25 & 26
2019

LILLE
France



The European leading partnering event for
innovation partnerships and **investment** in the
MedTech, diagnostic and digital health sectors

Organised by:



With the support of:



Institutional partners:



MedFIT at a glance

MedFIT is your opportunity to connect with international key innovators in the **MedTech, diagnostic and digital health sectors**.

As the **leading European partnering event**, MedFIT provides the ideal environment to help industry players to source early-stage assets, to facilitate the emergence of collaborative projects between big players, public research institutions, start-ups and SMEs, to increase licensing opportunities, to obtain funding and to facilitate market access.



700+
Delegates
(600 in 2018)



25+
Countries
represented

Who will you meet?



Sponsors

★ Gold ★



★ Silver ★



★ Bronze ★



★ Contributing ★



Steering Committee

Medtech, diagnostic companies



Stig Visti Andersen,
CEO,
Visticon



Amanda Baccarini,
VP, Global Marketing
& Strategic Innovation,
Becton Dickinson
Medical - Pharmaceutical Systems



Leo Kretzers,
General Manager,
Bakken Research Center,
Medtronic



Daniel Kroiss,
VP Chief Scientific Officer
CRM,
LivaNova



Stéphane Lavallée,
President,
Surgivisio



Louis de Lillers,
CEO,
CorWave



Antonin Marcault,
New Business Development
and Innovation Manager,
Philips



Nicolas Ploquin,
CEO,
Unilabs France



Cécile Réal,
CEO,
Endodiag



Nils Reimers,
R&D Manager,
Stryker

Associations, clusters



Marco Pintore,
General Manager
BioValley France



Florent Surugue,
Economic Development
and SMEs Director,
SNITEM



Grégory Vernier,
Executive Director,
MEDICALPS



Etienne Vervaecke,
General Manager,
Eurasanté & NHL Cluster

Academia, TTOs



Remke Burie,
Operations Director,
Technical Medical Centre,
University of Twente



Josephine Dixon-Hardy,
Director of Medical
Technology Innovation,
University of Leeds



Caroline Dreyer,
President
Conectus



Terry Gourlay,
Head of Department,
Biomedical Engineering,
University of Strathclyde



Michel de Mathelin,
Director,
I-cube lab



Abhay Pandit,
Scientific Director,
CURAM

Investors



Frank Bulens,
Partner,
Imec.xpand



James Greene,
Advisor,
Seroba Lifesciences



Joseph Nathan,
Director New Ventures,
Alfred Mann
Institute at the Technion

Inside the event



ONE-TO-ONE MEETINGS

Identify and connect with potential business, research partners and investors involved in the MedTech, diagnostic and digital health sectors



CONFERENCES AND ROUNDTABLE DISCUSSIONS

Gain insight from international experts and discover the latest industry trends



PITCH SESSIONS

Identify and promote innovative products, technologies and services



WOULD-BE CEO

Dedicated to MedTech entrepreneurs seeking a project or projects seeking a CEO



EXPERT MEETINGS

Get assistance from Medical Device Experts (regulatory affairs, market access...)



EXHIBITION

Highlight your company's visibility with other innovators in the MedTech, diagnostic and digital health sectors



TECHNOMED PARTY

Enjoy an informal networking evening

One-to-one meetings

The MedFIT partnering activity is the best way to **identify and connect** with potential business, research and financial partners.



John MacMahon
CEO, Mitre Medical (US)

«The philosophy of MedFIT's one-to-one meetings is sort of new in the sector. Not only you'll be able to connect with family to bigger funds, but also to the whole medtech community: Technology, cash and expertise are gathered in a single place.»



Remke Burie
Managing Director, University of Twente (NL)

«In Healthcare, it's all about collaborations between academia, industry and other players of the sector. With the business convention, you have time to meet and interact with them.»

Connect with 700 key players in the MedTech, diagnostic and digital health sectors at MedFIT 2019

How does it work?



LOG IN

to the partnering platform one month prior to MedFIT



REQUEST

meetings with participants of your choice



MEET

during MedFIT



DEVELOP

new collaborations and partnerships

Powered by:



Expert meetings



30
Minute
Meetings



Mathieu Charleux
Medical Devices Consultant, MD 101 (FR)

«Face-to-face meetings are the greatest advantage of the event. It really allows to exchange in-depth with all the MedTech players.»

Are you seeking assistance from Medical Device Experts?

Secure a free flash meeting by sending a request on MedFIT's partnering platform to meet with one of our experts.

The Experts are specialised in many fields, such as:

- Regulatory affairs / Quality assurance
- Production / Sourcing
- Preclinical evaluation / Clinical affairs
- Reimbursement
- Sales and marketing strategy
- Funding and financing
- Research & development
- Merger and acquisitions
- Human resources

Powered by:



Would-be CEO

Are you a MedTech entrepreneur seeking a project?

Do you have projects seeking a CEO?

Any MedTech entrepreneur looking for a project to get involved in is welcome to join MedFIT and particularly the "Would-be CEO" activity. Any incubator or technology transfer entity looking for an entrepreneur to lead their start-up or help launch their project is also welcome to join.

June 26th | 11.00 am - 12.30 pm

Workshop Would-be CEO:

- Panorama of European entrepreneurial training programmes
- How I met my co-entrepreneur?

Pitch Sessions



Mirren Mandalia

Director, New Business Development,
Ethicon - part of the Johnson & Johnson Innovation family of companies (US)

«One of the things that struck me at MedFIT was the depth and breadth of innovation across Europe and beyond. The need for collaboration to drive innovation has never been higher.»

Present your innovative project at MedFIT thanks to four different Pitch Sessions:

START-UP SLAMS

The Start-up Slams are dedicated to **start-up companies** or **a companies in creation** seeking to raise seed financing round.

Pitch fees: Free for all MedFIT participants.

COMPANY SLAMS

The Company Slams are dedicated to **SMEs** seeking to raise a Series A or onwards financing round.

Pitch fees: €150 additional fees to the MedFIT registration fees if selected.

COLLABORATIVE AND LICENSING OPPORTUNITY PRESENTATIONS

The Collaborative and Licensing Opportunity Presentations are dedicated to **TTOs, universities, research institutes and companies** which have an asset and are willing to entail a **collaborative project** and/or an **opportunity to out-license**.

Pitch fees: Free for all MedFIT participants.

SERVICE PRESENTATIONS Sponsored by: **NAMSA**

The Service Presentations are dedicated to **service providers** and **technology platforms with an innovative offer**. Thanks to the Service Presentations, your company will gain more visibility!

Pitch fees: From €150 to €300 additional fees to the MedFIT registration fees if selected.



The selected candidates will receive advice and feedback («speed-mentoring») from a panel of experts. The winners will be awarded as the **most innovative projects in Europe**.



How does it work?



Apply

before
March 15th, 2019

Be selected

by a jury
of experts

Pitch

during MedFIT

Agenda | Day One

Tuesday, June 25th, 2019

	Conferences	Pitch Sessions	Meet the Experts	One-to-one Meetings
8:30 am 9:00 am	Name badge pick-up & Welcome coffee			
9:00 am 10:30 am	Connected devices redesign healthcare: How are MedTech companies adapting to this new environment?	Faster together: Which recent trends in academia-big players collaborations?	Start-up Slams > Session 1	Medtech Experts Flash meetings One-to-one Meetings
10:30 am 11:00 am	Networking break			
11:00 am 12:30 pm	Plenary Session: How to increase the number of MedTech unicorns in Europe?			
12:30 pm 2:00 pm	🍴 Lunch			
2:00 pm 3:00 pm	How are healthcare systems and health plans directly investing in innovative companies in Europe?	Final stretch to MDR/IVDR implementation: How are companies revising their strategy to comply with the key requirements and associated timelines?	Collaborative and Licensing Opportunity Presentations > Session 1	Medtech Experts Flash meetings One-to-one Meetings
3:00 pm 4:00 pm	MedTech SMEs and start-ups: What are the strategies & initiatives to collectively answer to public tenders?	How will moving toward outcome-based payment models affect financing in MedTech?	Company Slams > Session 1	Medtech Experts Flash meetings One-to-one Meetings
4:00 pm 4:30 pm	Networking Break			
4:30 pm 6:00 pm	Big size vs mid-size companies: Different ways to deal with early-stage start-ups?	Service Presentations		
From 6:15 pm	🍷 Technomed Party			

Agenda | Day Two

Wednesday, June 26th, 2019

	Conferences	Pitch Sessions	Meet the Experts	One-to-one Meetings
8:30 am 9:00 am	Welcome coffee			
9:00 am 10:30 am	MedTech and digital industry: Which grounds for collaboration?	Company Slams > Session 2		
10:30 am 11:00 am	Networking break			
11:00 am 12:30 pm	Agnostic investors or pure players in the MedTech sector: Who is becoming prominent in the early-stage financing scene?	Would-be CEO Workshop: - Panorama of European entrepreneurial training programmes - How I met my co-entrepreneur?	Collaborative and Licensing Opportunity Presentations > Session 2	Medtech Experts Flash meetings One-to-one Meetings
12:30 pm 2:00 pm	🍴 Lunch			
2:00 pm 3:30 pm	What are the key factors of success in the relationship between an academic institution and a resulting spin-off?	Shifting to value-based care models: What are the challenges for the diagnostic tests and technologies?	Start-up Slams > Session 2	
3:30 pm 4:00 pm	Networking Break		🏆 Award Ceremony	
4:00 pm 5:30 pm	How do IT tools contribute to accelerate the process of completing clinical trials in the MedTech sector?			

- Track 1: Collaborate to innovate
- Track 2: Financing innovation
- Track 3: Market innovation
- Track 4: Digital innovation

Conferences

Supported by a prestigious Steering Committee, the **MedFIT conference programme** features the latest opinions on trending topics related to collaborative innovation partnerships, and focuses on market access, financing, the digitalisation of the sector and regulations.



Josephine Dixon-Hardy
Director of Medical Technologies Innovation,
University of Leeds (UK)

« I was very pleased to find people with interests that are very relevant to things we want to know about, which isn't just about industry or just about academia, but how the two work together. That was well addressed in the programme. »



Kayar Raghavan
Investor Mentor & NED,
London Business Angels (UK)

«Excellent animated panel discussions at MedFIT 2018. Ever so satisfying to discuss in front of a knowledgeable audience.»



Tamar Raz
CEO, Hadasit (IL)

«Knowing the market is very important; The MedFIT conferences provide great opportunities to learn more and gain insight on new rules and best practices.»

June 25th | 11.00 am - 12.30 pm

Plenary Session: How to increase the number of MedTech unicorns in Europe?

Europe is currently benefiting from a dynamic MedTech start-up ecosystem. However, not so many of these start-ups succeed in scaling-up. What are the possible strategies and paths to get bigger on MedTech market in Europe? What do we lack in order to accompany the scaling-up of MedTech companies? How to grow the private equity and stock markets to enable more frequent success in that process? How to ensure that the development and consolidation of the sector are also fuelled by MedTech SMEs merger and acquisition deals?

Track 1: Collaborate to innovate

#Licensing #Partnerships #R&D

Track 2: Financing innovation

#VCs #Startups #Investors

Track 3: Market innovation

#Regulation #BusinessModels #Strategy

Track 4: Digital innovation

#AI #Data #Transformation

Speakers

Over 60 international speakers will share their vision and experience. Among them:

Abdullah Albeyatti
Co-Founder & CEO
Medical Chain

Frank Bulens
Partner
Imec.xpand

Rajan Patel
CEO
iO Life Science

Alain Chevallier
Partner
Truffle Capital

Elena Kyriacou
Head of Marketing and
Communications
Regulatory Affairs
Professionals Society
Switzerland

Steven Dodsworth
CEO
DHealth

Ilya Kazi
Partner
Mathys & Squire LLP

Alain Pujol
Head of international affairs,
Angels Santé
EIT Health Investor
Network

Yvan Malepart
CEO
Macopharma

Santiago Ini
Director of Business
Development - Life Science
T3-Technion Technology
Transfer

Eleonora Mantovani
Programme Associate
RebelBio-SOSV

Brigitte Lavoie
Visiting Fellow
University of
Southampton

Josep Sanfeliu
CEO
Asabys Partners

Tsafrir Kolatt
CEO
Fertigo-medical

Aly Talen
Co-Founder & Sr. VP Business
Development
Genae

Track 1: Collaborate to Innovate

#Licensing #Partnerships #R&D

June 25th | 9.00 am - 10.30 am

Faster together: Which recent trends in academia-big players collaborations?

The shifting MedTech landscape has led big industry players to seek new collaborations to support their R&D needs rather than in-house efforts, initiating fresh ways to partner with academic institutions and speeding-up market access. On which needs are these collaborations focusing and what are the main reasons driving big players to partner with academia? To what extent are academia and industry developing common frameworks, protocols and processes to enable efficient collaboration?

June 25th | 4.30 pm - 6.00 pm

Big size vs mid-size companies: Different ways to deal with early-stage start-ups?

Start-ups with new medical technology on the market are becoming overpriced. Therefore, large and mid-size companies are showing a growing interest for earlier stage MedTech companies through R&D collaboration and licensing deals when looking outside for new R&D. Which strategies are those companies pursuing? Is there a difference of pattern between big and mid-size companies approaches when dealing with early stage investment and assets?

June 26th | 2.00 pm - 3.30 pm

What are the key factors of success in the relationship between an academic institution and a resulting spin-off?

Networking opportunities, use of laboratories and research cooperation are key resources universities can provide to their spin-offs in their further development. How can these ventures make their academic institution of origin a long-term partner? Which benefits do universities have when continuing to provide the start-up with the support required? Are there some ideal routines and guidelines to create a profitable and long-lasting collaboration for both?

Track 2: Financing Innovation

#VCs #Startups #Investors

June 25th | 2.00 pm - 3.00 pm

How are healthcare systems and health plans directly investing in innovative companies in Europe?

Healthcare systems and health plans have been a growing source of innovation investment and their interest in financing start-up companies and new technologies appears to be at its peak. Facing a twofold challenge to improve patient care while cutting costs, which assets are healthcare systems and health plans targeting? Is this ad-hoc innovation investment or can we observe more permanent and strategic approaches?

June 25th | 3.00 pm - 4.00 pm

How will moving toward outcome-based payment models affect financing in MedTech?

Moving toward value-based care models, MedTech companies have seen increasing price pressures and the necessity to improve patient outcomes. When it comes to demonstrate the improvements in patient outcomes, it may prove longer for a company to see significant financial return. How are the new outcome-based payment models changing the way innovation is perceived? How is quality measured and how are investment criteria evolving? Who takes on risk in a value-based care model? How to ensure improved communication within the payers' community to ease funding and reimbursement?

June 26th | 11.00 am - 12.30 pm

Agnostic investors or pure players in the MedTech sector: Who is becoming prominent in the early-stage financing scene?

Seed and Series A investments are critical to transforming new ideas into products and moving start-up teams into small businesses. From investors with a varied degree of specialisation to totally agnostic players only focusing on MedTech, who are the main players at these financing stages? What is the significance of the amount of early-stage investment today for cross-industry funds, specialised healthcare funds and pure players in the MedTech industry respectively?

Track 3: Market Innovation

#Regulation #BusinessModels #Strategy

June 25th | 2.00 pm - 3.00 pm

Final stretch to MDR/IVDR implementation: How are companies revising their strategy to comply with the key requirements and associated timelines?

EU new regulations are introducing an enhanced framework around the definition, supervision, traceability and risk-based classification system for medical device equipment. They will shortly apply after a transitional period: May 2020 for the medical devices and May 2022 for in-vitro diagnostic medical devices. How has the upcoming deadline impacted the MedTech and diagnostic players both from a European point of view and for foreign companies conducting business in Europe? What long term implications may this new legislation have on innovation and market investment? How are companies and regulatory authorities dealing with the remaining uncertainties?

June 25th | 3.00 pm - 4.00 pm

MedTech SMEs and start-ups: What are the strategies & initiatives to collectively answer to public tenders?

Public procurement can represent a major barrier for SMEs and start-ups as a majority of public tenders use lowest prices as the main selection criterion. Making it easier for SMEs to access public procurement opportunities could improve the purchasing of innovative solutions allowing public bodies to deliver a more efficient and valuable healthcare. The EU has led the way, initiating a series of initiatives to increase access to procurement markets for SMEs. Where are we in these innovative procurement practices? How are start-ups and SMEs cooperating in this context to compete with bigger players for public tenders?

June 26th | 2.00 pm - 3.30 pm

Shifting to value-based care models: What are the challenges for the diagnostic tests and technologies?

Health systems worldwide move from treatment to prevention, and from volume-based to value-based care model: Diagnostics can deliver significant improvements eased by the huge opportunities offered by digitalisation. As diagnostic services are a pivotal stage in patient care, early diagnosis can increase the probabilities of a positive outcome for patients and save costs of further treatment. How are the diagnostic providers aligning with value-based care? From diagnostic imaging to companion diagnostics, this panel discussion will explore the key challenges and share best practices for this strategic industry of the shifting healthcare system.

Track 4: Digital Innovation

#AI #Data #Transformation

June 25th | 9.00 am - 10.30 am

Connected devices redesign healthcare: How are MedTech companies adapting to this new environment?

Digital health technology and services are growing fast, offering a wide new range of connected devices, transforming and personalising the way care is delivered. Information and data generated by medical technologies, paired with the advances in AI should play a vital role in improving health outcomes and making health systems more efficient. How are innovative companies, large and small, adapting their business models? How do they deal with the flow of data and the legal and regulatory related issues?

June 26th | 9.00 am - 10.30 am

MedTech & digital industry: Which grounds for collaboration?

The MedTech sector has been subject to a substantial transformation during the past decade due to the arrival of new digital technologies and is now facing a growing inspiration from digital disrupters and tech giants expanding their healthcare reach through mergers and acquisitions. As more collaboration and integration across companies and sectors will be a vital part of the next wave of innovation what are the recent trends in jointly developing cutting-edge medical devices technologies? To what extent are MedTech and digital industry working together to deliver new products and services for patients? Which collaborative models are emerging? What are the successful examples, benefits, limits and constraints to these collaborations?

June 26th | 4.00 pm - 5.30 pm

How do IT tools contribute to accelerate the process of completing clinical trials in the MedTech sector?

Clinical data and evaluation of that clinical data is an explicitly defined legal requirement for medical devices. Solutions to fast-track market access may emerge from wearables and data analytics programs and allow a stronger and more efficient patient engagement and monitoring. What impact and scalability do these IT solutions have on the medical device clinical trial design? How are they integrated in the market access strategies of MedTech players?

Hosted Events




DERMA, an Interreg 2 Seas project, aims to develop **new interventions for the management and treatment of dermal ulcers and related skin conditions, including stomas**. By addressing market and patient need, the project will deliver advanced new technologies ready for exploitation by industry to manufacture improved products for the treatment of patients.

Challenge: By 2025 more than 25% of Europeans will be 65 or older, a vulnerable group in relation to illness. This is a cross-border phenomenon that will challenge healthcare providers. Ulceration of the extremities of this group is a major societal challenge. Moreover the presence of diabetes, cardiovascular diseases, fungating tumours and long-term immobilization, exposes all age groups to dermal ulceration. To tackle effectively this growing issue, new improved technologies and management options to reduce costs and improve outcomes are needed.

Objectives: The main scientific objectives of DERMA are to design, develop and evaluate an odour-absorbing, antimicrobial wound dressing and a dressing with diagnostic capability to indicate wound status.

Partners:



This project is co-financed by the European Regional Development Fund



SmartHealth



SmartHealth is a 2-year cross-border project dedicated to **cooperation and collaboration between startups and care institutions**.

Context:

Care institutions and startups are not well connected but it seems that on both sides needs and solutions could be proposed to better take care of our Health institutions. The model of a contest between startups answering a challenge and hospitals/care institutions proposing a contest is one of the way to boost collaboration and promote innovation for care institutions.

Goals:

- Promote innovation usage in care institutions
- Develop collaboration and cooperation between innovative startups and care institutions
- Promote cross border collaboration
- Provide Services to help companies develop abroad

Focus:

Digital technology development in health sector is transforming how we provide care and services to the patient. We are experiencing a disruption that aims to improve outcomes for patients, and provide cost benefits for healthcare providers.

Partners:



This project is co-financed by the European Regional Development Fund

Hosted Events



IMODE is organising its **third annual convention** during MedFIT with a morning conference the 25th of June. IMODE will also hold a stand during MedFIT convention and participate to MedFit one-to-one meetings.

About Imode:

IMODE is a collaborative research project for multicomponent pharmaceutical products (co-amorphous and co-crystals) and medical devices that are loaded with bioactive molecules. Started in 2016, the IMODE project is funded by the European Interreg 2 Seas programme and co-financed by the European Regional Development Fund (ERDF).

Objectives:

The project's overall objective is to bring together the specific transdisciplinary skills and experiences of partners (academic research groups, development agencies, SMEs) in order to provide the 2 Seas Area with strategic advantages for innovative pharmaceutical and medical applications. The IMODE project is motivated by an unmet need to develop solutions to addressing societal challenges to improve healthcare and provide novel and effective medication for various cardiovascular or gastro-intestinal conditions that lack or have inadequate treatment, all while keeping medical costs low.

Partners:



This project is co-financed by the European Regional Development Fund



CoBra – Technical Workshop on Brachytherapy will be held during MedFIT with an **after-noon conference** the 25th of June. CoBra will also hold a stand during MedFIT convention and participate to MedFIT one-to-one meetings.

Technological innovation for biopsy and brachytherapy under MRI control, in order to improve diagnosis and treatment of localised cancers

Clinical context:

Prostate cancer is the fourth most common cancer in Europe, for both combined sexes and the second most common cancer in men. Treatment of such cancer can be performed by surgery, external radiotherapy (RT) or brachytherapy. Surgery consists in removing the entire prostate, while RT involves irradiating the target volume with a particle accelerator. Brachytherapy is a technique better tolerated by patients, aiming to irradiate a target volume by placing radioisotopes emitting low or high ionizing radiation in it or in its contact, only in one intervention. However it presents also certain practical limits, such as: manual handling of radioactive needles that raises fears among practitioners; impotence, incontinence and trauma of patient.

Objectives:


The CoBra project aims to improve the quality of both diagnosis and treatment of localized cancers, by developing a new medical robot prototype for brachytherapy and biopsy under guidance of MRI. The overall objective of the project is to improve the accuracy of cancer diagnosis, and increase the accuracy of treatment, increasing cure rates and minimising side effects. The prostate and other soft tissues will be the main localized cancers of interest in the CoBra project.

Partners:



This project is co-financed by the European Regional Development Fund

Hosted Events



Mat(t)isse
Bioresorption
for reconstruction

Interreg
France-Wallonie-Vlaanderen
EUROPEAN UNION
EUROPEAN REGIONAL DEVELOPMENT FUND
MAT(T)ISSE

Nearly 1 out of 8 European women will be affected by a breast cancer during her life. The main surgical intervention to cure breast cancer today is mastectomy (73%) which remains a complicated intervention, often leading to a loss of self-esteem, sexual issues as well as a need for body acceptance. Only 20% of these women benefit from a breast reconstruction, either with silicone implants or transplants of tissues, requiring several interventions and presenting clinical risks and hurdles.

MAT(T)ISSE project aims to address these clinical challenges by developing, with the support of a multidisciplinary partnership across France and Belgium, a brand new solution for breast reconstruction. The innovation will consist of a 3D-printed bioresorbable and textile matrix to facilitate the transplant of tissues, as well as to guide the breast reconstruction process. This breakthrough innovation opens the way for a personalised and safer breast reconstruction, in a single intervention.

MAT(T)ISSE partners are delighted to invite you to a workshop on the 26th June to participate to the ongoing revolution in implants!

Partners:

CHU LILLE **ensait** **eurasanté** Invest for Success **MateriaNova** MATERIALS R&D CENTRE

sirris **UMONS** University of Mons **JP-TEX**

This project is co-financed by the European Regional Development Fund

Partners

Sponsors

BOSTON HEALTHCARE **eit Health** **ICOSA** European Patent & Trade Mark Attorneys **iH** innovHealth EVERYTHING FOR LIFE Customized Europe France-Gene

macopharma BIOTHERAPY DESIGNED FOR LIFE **Medtronic** **NAMSA**

Supporters

asebio SPANISH BIOMATERIALS ASSOCIATION **ATLANPOLE** biotherapies **BIOCITY** **bioPmed** BIOMATERIALS INNOVATION ECOSYSTEM **BioPartner** **Busi** Business Support Initiative

UK Science & Innovation Network Department for International Trade **evamed** LEARNER'S LEADERSHIP IN BIOLOGICAL MEDICINE **FRONDS** **FLAMED** The independent additive manufacturing platform **flanders.bio** **France Innovation**

FREE MIND Non-Dilutive Funding Experts **HealthValley** Netherlands **Hospital & Healthcare Management** www.hhsglobal.com **hub.brussels** **ID2Santé** Innovation and Entrepreneurship for Health Care & Biotech **innoget**

INSTITUT CARNOT STAB Sciences et technologies pour les applications de la biomédecine **Invest in Grenoble-Alps** **JBA** Japan Biotechnology Association **KIWANO** INNOVATION **leti** ceatech **LSI** Life Science Inkubator

MANDALA INTERNATIONAL **medicon valley alliance** Creating regional solutions **MEDILINKUK** **MEDTECH PLUS** **NORMANDIE INCUBATION** **OLU HEALTH**

Pôle des Microtechniques **PMT** inside everything **PRAMEX** INTERNATIONAL **PrYv** **RÉSEAU C.U.R.I.E.** **SATT NORD** **SEMIA** GÉNÉRATEUR DE STARTUPS

snitam **SOFA** Simulation Open Framework Architecture **Systematic** Paris Region Digital Ecosystem **TEMIS** TECHNOLOGIE MÉDICALE & BIOMÉDECINE **WORLD TRADE CENTER TWENTE**

Media Partners

BIOTECH GATE GLOBAL DATABASE **biotech.info** AU SERVICE DE LA BIOTECH EN EUROPE **DeviceMed** **GlobalData.** **HOSPIMEDIA** L'actualité des territoires de santé

INNOVATION Review **La gazette DU LABORATOIRE** **LEADERS LEAGUE** **MPN** MEDICAL PLASTICS NEWS - ADVANCING MEDICAL PLASTICS - **nöBEL** Smarter HealthTech in Europe

pharmalicensing Global Technology Marketplace **SCIENCES EN AVENIR** **TICpharma.com** #Actu #Santé #Numérique

Join MedFIT 2019

Registration fees*

Book online as soon as possible and save money:

	EARLY BIRD (Before February 3 rd , 2019 incl.)	REGULAR PRICE (From February 4 th until May 26 th , 2019 incl.)	LATE REGISTRATION (From May 27 th , 2019)
Mature company (>5 years old)	€ 687	€ 859	€ 945
Investor	€ 687	€ 859	€ 945
Non-profit organisation / TTO / Research institute	€ 527	€ 659	€ 725
Emerging company (≤5 years old) / SME (≤5 employees)	€ 383	€ 479	€ 527
Academic scientist / Clinician	€ 207	€ 259	€ 285

 Registration and information on www.medfit-event.com

Increase your company's visibility*



EXHIBIT AT MEDFIT

6m ²	€ 2,200 (Incl. 1 full pass* + 1 visitor pass**)
9m ²	€ 3,300 (Incl. 1 full pass* + 1 visitor pass**)
12m ²	€ 4,400 (Incl. 1 full pass* + 2 visitor pass**)
18m ²	€ 6,600 (Incl. 2 full pass* + 1 visitor pass**)



SPONSOR MEDFIT

GOLD	€15,000
SILVER	€10,000
BRONZE	€ 6,000

*The FULL PASS gives access to all MedFIT activities (access to the partnering platform to pre-organise one-to-one meetings)

**The VISITOR PASS gives access to all MedFIT activities (except the partnering platform)

There are many additional visibility opportunities, please contact us for a customised offer.

VENUE

Lille Grand Palais
1, Bd des Cités Unies
Lille (France)

CONTACT

Stéphanie Gautreau
sgautreau@eurasante.com
+33 (0)3 28 55 90 79



#MedFIT2019
@MEDFIT_EVENT

www.medfit-event.com